Iron Deficiency Anemia - Pipeline Insight, 2022

“Iron Deficiency Anemia - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Iron Deficiency Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Iron Deficiency Anemia Understanding

Iron Deficiency Anemia: Overview

Iron deficiency anemia arises when the balance of iron intake, iron stores, and the body's loss of iron are insufficient to fully support production of erythrocytes. Iron deficiency anemia rarely causes death, but the impact on human health is significant. Iron deficiency anemia is a common type of anemia — a condition in which blood lacks adequate healthy red blood cells. The symptoms of iron deficiency anemia can be mild at first and go unnoticed. Iron deficiency anemia signs and symptoms may include: Extreme fatigue, Weakness, Pale skin, Chest pain, fast heartbeat or shortness of breath, Headache, dizziness or lightheadedness, Cold hands and feet, Inflammation or soreness of your tongue, Brittle nails and others. Iron deficiency anemia occurs when body doesn't have enough iron to produce hemoglobin. Iron-deficiency anemia is diagnosed by blood tests that should include a complete blood count (CBC). Additional tests may be ordered to evaluate the levels of serum ferritin, iron, total iron-binding capacity, and/or transferrin. To treat iron deficiency anemia, iron supplements are usually recommended. Even if the cause of the iron deficiency can be identified and treated, it is still usually necessary to take medicinal iron (more iron than a multivitamin can provide) until the deficiency is corrected and the body's iron stores are replenished.

""Iron Deficiency Anemia - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Iron Deficiency Anemia pipeline landscape is provided which includes the disease overview and Iron Deficiency Anemia treatment guidelines. The assessment part of the report embraces, in depth Iron Deficiency Anemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Iron Deficiency Anemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Iron Deficiency Anemia R&D. The therapies under development are focused on novel approaches to treat/improve Iron Deficiency Anemia.

Iron Deficiency Anemia Emerging Drugs Chapters

This segment of the Iron Deficiency Anemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Iron Deficiency Anemia Emerging Drugs
• IOP Injection: MegaPro Biomedical

IOP injection is an iron oxide nanoparticle conjugated chemically with mPEG-silane, and is highly soluble in water. The IOP injection has been developed for two applications; (i) as a new MRI contrast agent and; (ii) as the first non-sugar based intravenous (IV) iron for treating iron deficiency anemia with fewer side effects and higher potency than current therapies. IOP injection was developed to provide a low incidence of hypersensitivity to the coating material (mPEG-SILANE). IOP injection is also intended for high uptake efficiency by the reticuloendothelial system (RES) to provide an efficacious, as well as safe, treatment strategy for the treatment of iron deficiency anemia in non-dialysis dependent CKD patients. The Phase II study is being conducted to establish the maximum tolerated dose of i.v. IOP Injection (MPB-1514) in Part 1 and to evaluate the safety and efficacy of the maximally tolerated dose of IOP Injection with different infusions schemes in Part 2.
• CSJ137: Novartis

CSJ 137, an intravenously administered biological product is being developed by Novartis for the treatment of iron-deficiency anaemia. The drug is being investigated in Phase II clinical trials for the treatment of patients with iron-deficiency anaemia.

Further product details are provided in the report……..

Iron Deficiency Anemia: Therapeutic Assessment

This segment of the report provides insights about the different Iron Deficiency Anemia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Iron Deficiency Anemia

There are approx. 6+ key companies which are developing the therapies for Iron Deficiency Anemia. The companies which have their Iron Deficiency Anemia drug candidates in the most advanced stage, i.e. Phase II include, MegaPro Biomedical.
• Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Iron Deficiency Anemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Iron Deficiency Anemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Iron Deficiency Anemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Iron Deficiency Anemia drugs.

Iron Deficiency Anemia Report Insights
• Iron Deficiency Anemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Iron Deficiency Anemia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Iron Deficiency Anemia drugs?
• How many Iron Deficiency Anemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Iron Deficiency Anemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Iron Deficiency Anemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Iron Deficiency Anemia and their status?
• What are the key designations that have been granted to the emerging drugs?